London, UK--(Marketwire - January 3, 2008) -
SkyePharma PLC
U.S. FDA Approves New Sular Formulation
LONDON, UK, and Atlanta, USA, 3 January 2008 -- SkyePharma PLC (LSE: SKP) and
Sciele Pharma, Inc (NASDAQ:
SCRX) announce that the U.S. Food and Drug
Administration (FDA) has approved all four dosage strengths of the new Sular®
formulation. Sular® is a calcium channel blocking agent for the treatment of
high blood pressure. The new Sular formulation utilizes SkyePharma's patented
GEOMATRIX™technology, which provides a lower dose of Sular® for each of its
current doses. The expected launch for the new Sular® formulation is during
the first quarter of 2008.
SkyePharma will receive US$2 million (GBP1 million) upon the approval and also low
mid single digit royalties on net sales of new Sular®. SkyePharma will also be
manufacturing the new Sular® formulation at our Lyon manufacturing facility.
Dr Ken Cunningham, COO of SkyePharma said: "This new Sular® formulation is a
further example of the versatility of the GEOMATRIX™technology and will
provide an additional revenue stream for SkyePharma."
For further information please contact:
SkyePharma PLC Frank Condella +44 20 7491 1777
Ken Cunningham
Peter Grant
Financial Dynamics
(UK Enquiries) David Yates +44 20 7831 3113
Deborah Scott
Trout Group (US Enquiries) Christine Labaree +1 617 583 1308
Seth Lewis
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new
formulations of known molecules to provide a clinical advantage and life-cycle
extension. The Company has eleven approved products in the areas of oral,
inhalation and topical delivery. The Group's products are marketed throughout
the world by leading pharmaceutical companies. For more information, visit
www.skyepharma.com
About Sciele Pharma, Inc.
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing
and development of branded prescription products focused on Cardiovascular/
Metabolic, Women's Health and Pediatrics. The Company's Cardiovascular/Metabolic
products treat patients with high cholesterol, hypertension, high triglycerides,
unstable angina and Type 2 diabetes; its Women's Health products are designed to
improve the health and well-being of women and mothers and their babies; and its
Pediatrics products treat allergies, asthma, coughs and colds, and attention
deficit/hyperactivity disorder (ADHD). Founded in 1992 and headquartered in
Atlanta, Georgia, Sciele Pharma employs more than 900 people. The Company's
success is based on placing the needs of patients first, improving health and
quality of life, and implementing its business platform - an Entrepreneurial
Spirit, Innovation, Speed of Execution, Simplicity, and Teamwork.
This information is provided by RNS
The company news service from the London Stock Exchange